stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Current ratio
Genmab A/S Sponsored ADR's current ratio at the end of the quarter to 30 June 2026 was 2.5×, up 0.4× from fiscal 2025 (2.0×). Over the past ten years it has ranged from 2.0× (fiscal 2025) to 18.5× (fiscal 2017) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.0× | (61.43%) |
| FY2024 | 5.2× | (60.71%) |
| FY2023 | 13.3× | (14.29%) |
| FY2022 | 15.6× | 7.35% |
| FY2021 | 14.5× | (3.31%) |
| FY2020 | 15.0× | 0.76% |
| FY2019 | 14.9× | (11.22%) |
| FY2018 | 16.8× | (9.52%) |
| FY2017 | 18.5× | 55.86% |
| FY2016 | 11.9× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 2.5× | 12.49% |
| Mar 2026 | 2.2× | 8.04% |
| Dec 2025 | 2.0× | (66.49%) |
| Sep 2025 | 6.0× | (2.94%) |
| 26 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 16.7× |
| BNTX BioNTech SE Sponsored ADR compare | 8.6× |
| RVMD Revolution Medicines, Inc. compare | 8.4× |
| INCY Incyte Corporation compare | 3.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 3.6× |
| INSM Insmed, Inc. compare | 2.9× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 2.5× |
| GMAB Genmab A/S Sponsored ADR | 2.5× |
| RPRX Royalty Pharma PLC compare | 1.3× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement